Genentech Sues Rivals Over Generic Anti-Viral Drug Plans

Law360, Washington (September 5, 2013, 3:29 PM EDT) -- Genentech Inc. and a unit of parent company Roche Holding Ltd. sued Mylan Pharmaceuticals Inc. and an Actavis Inc. unit Wednesday in Delaware federal court, accusing their rivals of infringing a patent covering anti-viral Valcyte with their planned generic versions of the drug.

Genentech and Roche Palo Alto LLC say that Mylan and Watson Laboratories Inc.–Florida’s planned generic versions of valganciclovir hydrochloride — a 450-milligram tablet for Mylan and a 50-milligram-per-milliliter oral solution for Watson — infringe U.S. Patent Number 6,083,953 covering Valcyte.


“On information...
To view the full article, register now.